leisure time -WSS

leisure time

author：fashion 2025-09-28 02:29:13 - browse：273

Adam's take main illustration — Molly Ferguson/STAT

The approval Friday of Bluebird Bio’s gene therapy for sickle cell disease should have been a momentum-swinging achievement for the long-struggling biotech. Instead, the company mispriced its new drug and fumbled a pivotal financial lifeline.

The consequences of these strategic blunders — arguably, self-inflicted — could imperil Bluebird’s independence, perhaps even its survival.

Bluebird priced Lyfgenia at $3.1 million, while Vertex Pharmaceutical set the cost of Casgevy, its competing sickle cell treatment also approved on Friday, at $2.2 million. Not only is Lyfgenia significantly more expensive, but its prescribing label carries a “black box” safety warning, which requires patients undergo regular blood monitoring for cancer risk. Casgevy has no similar monitoring requirement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Kristina Burow of ARCH Venture Partners shares her next big bets STAT

hotspot

WSS

Trump got a 'target letter.' What is one and what does it mean?

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

Researchers separate signal from noise in heart wearable data

Why getting cancer drugs just got harder for rural patients

Celebrate National Dole Whip Day for 3 days this week at Disney

AstraZeneca loses challenge to Medicare drug price negotiation

focus

leisure time

Wikipedia

Duchenne breakthrough therapy leaves behind pioneering families

Russia strikes Ukraine's critical port facilities in Odesa after halting grain deal

Sports medicine is finally prioritizing gender equality

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Seattle police shoot person suspected in downtown stabbing

In age of alternative facts, a scholarly course on calling out crap

RSV vaccines may be linked to small increased risk of developing GBS

As demand for Covid shots wanes, Moderna seeks its next success

STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

focus

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Norman Reedus' Daryl Dixon

How to address the problem of discarded donor organs

Lindsay Lohan welcomes 1st child with husband Bader Shammas

Lindsay Lohan welcomes 1st child with husband Bader Shammas

Celebrate National Dole Whip Day for 3 days this week at Disney

hotspot

focus

knowledge

Wikipedia